Young child with Doctor

Latest press releases

Thursday, 26 April 2012
David Brennan to retire as AstraZeneca’s Chief Executive Officer AstraZeneca today announced that Chief Executive Officer and Board member, David Brennan has decided to retire.
Thursday, 26 April 2012
AstraZeneca PLC First quarter results 2012 First quarter results reflect challenging revenue picture. Pipeline strengthened by Amgen collaboration, the agreement to acquire Ardea Biosciences and positive CHMP opinion for FORXIGA(TM) (dapagliflozin) in Europe.
Wednesday, 25 April 2012
AstraZeneca and The Medicines Company announce global collaboration in acute ischaemic heart disease Global Development and Commercialisation Agreement to Begin with Co-Promotion of BRILINTA (ticagrelor) in United States.
Monday, 23 April 2012
AstraZeneca to acquire Ardea Biosciences for $1 billion (net of existing cash) including lead product lesinurad in Phase III development for gout AstraZeneca and Ardea Biosciences, Inc. (Ardea) today announced that they have entered into a definitive merger agreement, pursuant to which AstraZeneca will acquire Ardea, a San Diego, California-based biotechnology company focused on the development of small-molecule therapeutics.  Ardea’s clinically most advanced product candidate, lesinurad (formerly known as RDEA594), is currently in Phase III development as a potential treatment for the chronic management of hyperuricaemia in patients with gout.
Friday, 20 April 2012
FORXIGA (dapagliflozin) receives positive CHMP opinion in the European Union for the treatment of type 2 diabetes AstraZeneca and Bristol-Myers Squibb Company today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended the approval of FORXIGA (dapagliflozin) tablets for the treatment of type 2 diabetes, as an adjunct to diet and exercise, in combination with other glucose-lowering medicinal products including insulin, and as a monotherapy in metformin intolerant patients.
Monday, 2 April 2012
AstraZeneca and Amgen announce collaboration to jointly develop and commercialise clinical-stage inflammation portfolio AstraZeneca and Amgen today announced an agreement to jointly develop and commercialise five monoclonal antibodies from Amgen’s clinical inflammation portfolio: AMG 139, AMG 157, AMG 181, AMG 557 and brodalumab (AMG 827).
Friday, 30 March 2012
US DISTRICT COURT FINDS SEROQUEL XR® FORMULATION PATENT VALID AND INFRINGED AstraZeneca today announced that the US District Court for the District of New Jersey has found the formulation patent protecting SEROQUEL XR® (quetiapine fumarate) extended release tablets to be valid. The court also ruled that Anchen Pharmaceuticals, Inc., Osmotica Pharmaceutical Corporation, Torrent Pharmaceuticals Limited, Torrent Pharma Inc., Mylan Pharmaceuticals Inc. and Mylan Inc. have infringed the SEROQUEL XR formulation patent.  The SEROQUEL XR formulation patent expires in 2017.
Monday, 26 March 2012
US court denies preliminary injunction application against the FDA and dismisses AstraZeneca’s lawsuit without prejudice On 23 March 2012, the US District Court for the District of Columbia issued an opinion and order in AstraZeneca’s lawsuit against the US Food and Drug Administration (FDA) regarding final marketing approval of generic quetiapine. The Court denied the company’s request for a preliminary injunction and dismissed the lawsuit without prejudice.
Thursday, 22 March 2012
UK court finds SEROQUEL XR® formulation patent invalid AstraZeneca today announced that the High Court in the UK has rendered its opinion on the formulation patent protecting SEROQUEL XR® (quetiapine fumarate) prolonged-release tablets currently pending in the UK court. The court found the formulation patent protecting SEROQUEL XR (marketed as SEROQUEL XL in the UK) to be invalid. The patent was challenged by Accord Healthcare Limited, Intas Pharmaceuticals Limited, Hexal AG and Sandoz Limited, Teva UK Limited, and Teva Pharmaceutical Industries Limited.
Tuesday, 20 March 2012
Remaining TC-5214 Phase III efficacy studies do not meet endpoint, regulatory filing will not be pursued AstraZeneca and Targacept, Inc. today announced top-line results from the remaining Phase III studies investigating efficacy, tolerability and safety of TC-5214 as an adjunct therapy to an antidepressant in patients with major depressive disorder (MDD) who did not respond adequately to initial antidepressant treatment. RENAISSANCE 4 and RENAISSANCE 5, both efficacy and tolerability studies, did not meet the primary endpoint of change on the Montgomery-Asberg Depression Rating Scale (MADRS) total score after eight weeks of adjunct treatment with TC-5214 as compared to placebo.
Bookmark & Share